Research paper

Biosynthetic homeostasis and resilience of the complement system in health and infectious disease

Esther Willems a,b,c,e, Wynand Alkema d, Jenneke Keizer-Garritsen c, Anouk Suppers c, Michiel van der Flier e, Ria H.L.A. Philipsen a,b, Lambert P. van den Heuvel c,f, Elena Volokhina c,f, Renate G. van der Molen a, Jethro A. Herberg e, Michael Levin e, Victoria J. Wright e, Inge M.L. Ahout f, Gerben Ferwerda a,b, Marieke Emonts h,i,j, Navin P. Boeddhak, Irene Rivero-Calle l, Federico Martinon Torres l, Hans J.C.T. Wessels c, Ronald de Groot a,b, Alain J. van Gool c, Jolein Gloerich c, Marien I. de Jonge a,b

Keywords: Clusterin, C-reactive protein (CRP), Infectious disease, Complement system, Multiple reaction monitoring (MRM), Targeted mass spectrometry

Available online 29 June 2019
Accepted 6 June 2019
Received in revised form 6 June 2019
Received 8 April 2019

Article history:

Background: The complement system is a central component of the innate immune system. Constitutive biosynthesis of complement proteins is essential for homeostasis. Dysregulation as a consequence of genetic or environmental cues can lead to inflammatory syndromes or increased susceptibility to infection. However, very little is known about steady state levels in children or its kinetics during infection.

Methods: With a newly developed multiplex mass spectrometry-based method we analyzed the levels of 32 complement proteins in healthy individuals and in a group of pediatric patients infected with bacterial or viral pathogens.

Findings: In plasma from young infants we found reduced levels of C4BP, ficolin-3, factor B, classical pathway components C1QA, C1QB, C1QC, C1R, and terminal pathway components C5, C8, C9, as compared to healthy adults; whereas the majority of complement regulating (inhibitory) proteins reach adult levels at very young age. Both viral and bacterial infections in children generally lead to a slight overall increase in complement levels, with some exceptions. The kinetics of complement levels during invasive bacterial infections only showed minor changes, except for a significant increase and decrease of CRP and clusterin, respectively.

Interpretation: The combination of lower levels of activating and higher levels of regulating complement proteins, would potentially raise the threshold of activation, which might lead to suppressed complement activation in the first phase of life. There is hardly any measurable complement consumption during bacterial or viral infection. Altogether, expression of the complement proteins appears surprisingly stable, which suggests that the system is continuously replenished.

Fund: European Union’s Horizon 2020, project PERFORM, grant agreement No. 668303. © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The complement system is one of the oldest immune defense mechanisms and is highly conserved in all vertebrates [1]. This network of
Research in context
Evidence before this study

Knowledge of the complement system in pediatric infectious diseases is still limited; presumably due to the lack of methods to study multiple complement proteins simultaneously. The complement system has different strategies to recognize specific pathogens, which could imply putative pathogen-specific depletion of the affected complement proteins and pathways. For several complement proteins conflicting results are reported on possible gender-dependent effects and lower steady state levels during childhood.

Added value of this study

In this study we demonstrate the application of a newly developed method to measure 32 complement proteins in multiplex using sensitive and specific targeted mass spectrometry. We compared healthy individuals ranging from 0 to 55 years of age and observed lower complement levels in infants for a subset of the measured complement proteins. However, we did not observe a gender effect for either the healthy or infected patient group. There was no distinct complement level signature for specific infections. We show that the complement levels remain stable during infection, with the exception of CRP and clusterin.

Implications of all the available evidence

The levels of several classical pathway proteins are lower in the first year of life; whereas most inhibiting factors are already at adult levels. This might indicate that complement activation is more suppressed in newborns. During infections the levels of complement proteins remain stable, except for CRP and clusterin, which indicates that the complement proteins are continuously replenished to maintain an immune response.

Proteins, forming a sophisticated biological reaction system, play an important role in the orchestration of both the innate and adaptive immune defense and is involved in the repair or clearance of damaged cells [2–4]. Not surprisingly, unpremeditated activation of the complement system results in inflammatory syndromes, autoimmunity disorders, neuro-degenerative diseases, biomaterial rejection and cancer development [5–7].

Most of the approximately 50 complement proteins are constitutively expressed and mainly synthesized in the liver. The nearly 40 soluble constituents are highly abundant in blood as circulating inactive precursors. The complement system is activated via three main pathways: the classical, lectin and alternative pathway [7]. Activation of each of these proteolytic cascades leads to cleavage of complement components C3 and C5 which are key proteins in all activation pathways (Fig. 1). Tissue factors and coagulation proteins, such as kallikrein, thrombin, factors XIa, Xa, IXa, and plasmin, can also directly cleave C3 and C5. This extrinsic complement pathway clearly indicates interconnections between the complement and the coagulation system [8,9].

The specific cleavage products from the complement cascade act in multiple ways. They can induce inflammatory responses (C3a, C5a), enhance phagocytosis (C3b), and create pores (C5b–C9) in the pathogen’s membrane leading to lysis [2]. The main function of more than one third of the proteins in this extensive system is inhibiting unpremeditated or excessive activation, which emphasizes the importance of strict regulation of this intricate ‘trigger-ready’ system.

Interestingly, the complement system uses several different approaches to recognize and inactivate specific types of bacteria and viruses, as described by Stoermer et al. [10]. At the same time, various pathogens have developed their own unique strategies to evade the complement system as reviewed by Bennett et al. [11]. The evolutionary determined interplay between host and pathogen has resulted in this refined complex protein system, produced for continuous immune surveillance and homeostasis. This might have led to the pathogen-specific activation pathways, reflected by altered expression levels of pathway-specific components during infection. This would provide unique possibilities to diagnose pathogen-specific infections based on the complement protein profile. However, little is known about how infection influences the plasma complement protein levels.

Deficiencies in the complement system leading to reduced concentrations and/or less activity increase the vulnerability for infection, especially with invasive bacterial species like Neisseria meningitidis or Streptococcus pneumoniae [5,12,13]. Particularly newborns and young children are at high risk as their immune system is still under development [14–16]. Yet, knowledge of the complement system in children and its role in pediatric disease is still limited. Also little is known with respect to the production and basal levels of the complement proteins. Reference levels of all 40 circulating complement proteins are unreported and many diagnostic laboratories use their own databases to determine deviating concentrations. We therefore designed and developed a reproducible and specific method to measure complement proteins in multiplex, enabling the measurement of large numbers of plasma samples obtained from healthy individuals from different age groups, as described in this study.

Studies of complement levels (mainly C1 to C9, factor B, D, H, I and properdin) in newborns conducted between 1970 and 1995 described that most complement levels are at 50–70% of the adult values, rising to adult concentrations within 6 months [16–20]. Other studies in young infants have reported complement C3, C7 and factor D at adult levels or even higher [19,20]. In the last two decades, few studies have been performed to determine normal complement concentrations in children using standardized methods. Only recently studies have been conducted in which no significant age-dependent differences were found for C3, factor H, factor I and C1r/C1s for FHR-5 [21,22].

Furthermore, publicly available basal complement levels in adults, apart from C3 and C4 [23], mostly date back to the 1970’s [24]. However, a recent publication describes complement levels in adults (20–69 years) for 19 complement proteins measured by independent ELISAs, but focuses more on pathway and gender differences [25]. In conclusion, conflicting results are reported on several complement protein levels during childhood, possibly due to the use of less accurate techniques such as radial immunodiffusion and immunoelectrophoresis in older studies. Recent comprehensive studies on complement protein levels are based on adult levels, so it remains unknown if there are differences in complement levels in various age groups and if these levels change during infection.

Only a limited number of complement proteins are currently used in research and diagnosis, determined by singleplex ELISA or nephelometric tests [26]. Recently, liquid chromatography (LC), mostly combined with mass spectrometry (MS) detection, is increasingly used for protein quantitation in research and diagnostics [27–30]. Although mass spectrometry is not an immediate alternative for the ease-of-use and high-throughput immunoassays, the requirement of a few microliters of sample and its high specificity and reproducibility make LC-MS an attractive option [31]. Furthermore, LC-MS is a highly suitable method for multiplexed protein analysis, providing the possibility to capture a profile of proteins. This is highly relevant in the case of multi-factorial complement-mediated diseases, as a complete overview of all the complement proteins measured simultaneously will help to unravel mechanisms of complement-mediated diseases and may facilitate diagnosis and monitoring of treatment.

Our aim was to develop a multiplex reaction monitoring (MRM) assay targeting the 40 soluble plasma complement proteins to obtain a detailed protein abundance profile of the complement system. By
using stable isotope labeled internal standards we were able to identify and relatively quantify 64 targeted peptides, representing 32 complement proteins. Using this new assay, we compared the basal levels of these complement peptides in both healthy adults and healthy children. We also used this assay to perform a pilot study of 75 pediatric patients diagnosed with either a bacterial or viral infection to study differences in the complement system. Furthermore, we investigated patients infected with invasive bacterial pathogens at multiple time points to monitor complement kinetics during infection in more detail. In overall perspective, the complement system appears surprisingly resilient, which is probably due to high protein turnover, sustaining homeostasis in order to maintain its biological function. The high specificity and reproducibility of this multiplex complement assay has the potential to be applied for the diagnosis of complement-mediated diseases.

2. Materials and methods

2.1. Study approval for patients and healthy donors

For this study a group of 75 children (0–18 years) diagnosed with either a definite bacterial infection (n = 44), or a definite viral infection (n = 31) were selected. Bacterial or viral infection were determined by a positive blood culture or PCR, respectively. Of all subjects, plasma samples taken within 24 hours post-admission to the hospital were used. For 11 subjects with a definite bacterial infection additional plasma samples were collected at a further 2 time points - 48 hours post-admission and at recovery (ranging between 3 and 49 days). All samples were part of the EUCLIDS [32,33], IRIS [34] and VENTURIUS [35] studies, which were approved by the Medical Ethical Committees of the academic hospitals involved in these studies. Parents or guardians and children above 12 years old provided written informed consent. The selection was based on an equal distribution of the type of causative pathogen, gender and age.

Furthermore, plasma samples from 23 pediatric healthy subjects (0–5 years old) from a previous study [21] were included. The selection criteria for these pediatric controls and approval by Medical Ethical Committee have previously been described [21]. Additionally, 20 adult healthy volunteers (23–55 years) donated their blood for this study after informed consent and were collected according to the guidelines of the Human-related Research Committee Arnhem-Nijmegen. Exclusion criteria were: fever (>38.5 °C), symptoms of infection (bacterial or viral), chronic illness and immune suppressive medication.

Fig. 1. Schematic representation of the complement system, showing approximately 50 directly involved soluble and membrane-bound complement proteins. The complement system is activated through three different pathways: the classical, lectin, and alternative pathway. Activation of each of these proteolytic cascades leads to the cleavage of the central component complements C3 and C5. Complement factors are also active in extrinsic pathways. The multiplex MRM Complement assay targets proteins from the three main pathways, as indicated in green. Proteins indicated in orange are those that were excluded from the assay because of low abundance. Proteins indicated in red were not detectable with this method. Proteins in gray are not in the assay as they are mostly membrane bound or complexes.
Additional clinical data from all healthy subjects and patients enrolled in this study are summarized in supplementary table S1.

2.2. Sample collection

Patient plasma samples were collected and frozen as described previously (EUCLIDS [32,33], IRIS [34] and VENTURIUS [35]). The selected samples were shipped on dry ice and stored at −80 °C upon arrival. Plasma samples from the pediatric healthy subjects [21] and healthy adult volunteers were placed on ice immediately after collection and were processed within 1 h (10 min, 2500g, 4 °C). Aliquots were stored at −80 °C.

2.3. MRM method development

Out of >10.000 potential candidate peptides, representing 40 complement proteins, we selected 120 candidate target peptides in silico, with each 10 transitions, based on both technical and biological properties. We combined information from several sources (a.o. PeptideAtlas [36], Uniprot [37], dbSNP [38] and built-in restriction options of Skyline [39]), taking into account features including: uniqueness, length of the peptide, susceptibility to possible post-translational or chemical modifications, SNPs, isoforms, incomplete proteolysis, and hydrophobicity.

After mass spectrometric analysis of pooled digested plasma (5 controls and 5 patients) at least 2 peptides were selected for each protein subunit (n = 86), using the most predominant charge state and the 5 transitions with highest intensity. C-terminally 13C15N stable isotope labeled “heavy” peptides (Thermo, JPT) were used to optimize instrument settings for each peptide specific (cone voltage and collision energy) and to spike the samples for identification and relative quantification. Based on the results, a scheduled MRM method was created using retention time windows of 2 min each and was designed in such way that both endogenous and stable isotope labeled peptides could be analyzed with 3 transitions per precursor and at least 8 data points per chromatographic peak using dwell times of 30–50 ms.

2.4. Sample preparation

Samples were prepared in a randomized order. Total protein content was determined using the 2D Quant kit (GE Healthcare). Proteins were reduced with dithiothreitol (DTT) (1 μl 10 mM DTT/50 μg protein) for 30 min at RT. Reduced cysteines were alkylated through incubation with 2-chloroacetamide (CAA) (1 μl 50 mM CAA/50 μg protein) in the dark for 30 min at RT. Next, proteins were subjected to LysC digestion with 2-chloroacetamide (CAA) (1 μg trypsin/50 μg protein) for overnight digestion at 37 °C. Samples were spiked with a mix of C-terminally 13C15N stable isotope labeled “heavy” peptides (Thermo, JPT) and heavy labeled standard (H1 and H2), and the (L1 + L2)/(H1 + H2) * 100 ratio was determined for each peptide using an in-house developed MATLAB routine (version 2014b, The MathWorks, USA).

For each peptide the relative fragment ion intensities of the endogenous (light, L) and spiked heavy labeled standard (heavy, H) were compared using Pearson’s correlation. Transitions with a correlation of <0.6 (mainly due to high background signals) were considered as outliers and were excluded from the method. The intra-assay (injections on same day), inter-assay (injections on different days) and inter-operator (sample preparation by three different technicians) variability were assessed for each peptide by means of the coefficient of variation (CV%). For five repeated measurements of one pooled digested plasma sample (5 controls and 5 patients). The stability of the sample in the auto-sampler was determined for each peptide by the CV% of 13 injections with intervals of 4 h (total 52 h) of a pooled digested plasma sample. For all four tested specifications a cut-off CV of <20% was used for selection. The linear regression coefficient of determination (R2) was assessed for each peptide using a dilution series of a mix of all heavy labeled standards (0–5; 1; 5, 10; 50; 100; 250; 500; 750; 1000 fmol crude standard, synthesized by Thermo and JPT) spiked into pooled digested plasma, in duplicate.

The following statistical tests were performed and created using standard packages in R (v3.5.2): Pearson’s correlation, t-test with multiple testing correction, hierarchical clustering (1 – correlation as distance metric), random forest analysis (all 64 features, 500 iterations) and Principle Component Analysis (PCA). ANalysis Of VAriance (ANOVA) with Bonferroni’s correction for multiple testing was performed using Graphpad 5.03.

2.5. Mass spectrometric analysis

Samples were analyzed in randomized order using the Waters Acquity MClass UPLC Xevo TQ-S, equipped with an ionKey/MS sytem using a Waters peptide BEH C18, 130 Å, 1-7 μm, 150 μm×100mm iKey for chromatographic separation. The system was configured in direct injection mode. Peptides were eluted from the column using a 20 min linear gradient of 3 to 35% acetonitrile in 0–1% formic acid at a flow rate of 2 μl/min. The following MS conditions were used: ESI positive ionization mode, capillary voltage 4.0 keV, source temperature 120 °C, cone gas flow 30/1 h, nebulizer 7-0 bar, collision gas flow (0-15 ml/min). Optimal precursors and transitions and their corresponding cone voltage and collision energy (CE) voltages were set according to preceding optimization experiments.

2.6. Data processing and statistical analysis

Raw data were analyzed using Skyline software v4.2.0.18305 (MacCoss Lab, University of Washington, USA [39]). Typical settings applied included default peak integration, no peak smoothing, SScrCalc window of 10 arbitrary units, Q1 mass window of 0.7 Th, Q3 window of 1-0 Th, considered isotypes up to 3 amu. The dataset was manually inspected to ensure correct peak detection and integration.

The respective peak areas of both transitions were summed for the endogenous (L1 and L2) and spiked heavy labeled standard (H1 and H2), and the (L1 + L2)/(H1 + H2) * 100 ratio was determined for each peptide using an in-house developed MATLAB routine (version 2014b, The MathWorks, USA).

The following statistical tests were performed and created using standard packages in R (v3.5.2): Pearson’s correlation, t-test with multiple testing correction, hierarchical clustering (1 – correlation as distance metric), random forest analysis (all 64 features, 500 iterations) and Principle Component Analysis (PCA). ANalysis Of VAriance (ANOVA) with Bonferroni’s correction for multiple testing was performed using Graphpad 5.03.

2.7. Data sharing

The Skyline raw datasets can be found online in the Panorama public repository: https://panoramaweb.org/ikhShd.url

ProteomeXchange ID: PXD014264. All raw and processed data can be found in a Mendelea Data repository, DOI: 10.17632/bpss9cedd27.2

3. Results

3.1. Patient and healthy control characteristics

For this study 43 controls and 75 patients were selected from five European medical centers, situated in the Netherlands, UK and Spain. The pediatric patients had either a bacterial or viral infection. The following pathogens were detected in these patients: Streptococcus pyogenes, Neisseria meningitidis serogroup B, Streptococcus pneumoniae, Staphylococcus aureus, adenovirus, enterovirus, rhinovirus, or respiratory syncytial virus. Gender, age and type of infection were equally distributed over all groups (Fig. S1). The mean age for the adult controls

306 E. Willems et al. / EBioMedicine 45 (2019) 303–313
was 36 years, for the young controls and patients 3 years of age. Additional characteristics for patients and controls are shown in Table S2.

3.2. MRM assay design and validation

During development of the MRM assay, for each peptide target the peak area, background interference, correlation between fragmentation patterns, linearity, reproducibility, and robustness were assessed for both the endogenous and internal standard signals for all transitions. Based on these characteristics the two out of three best performing transitions were selected for a total of 86 peptides (Fig. 2). The average intra-assay variation (reproducibility), inter-assay variation (robustness) and inter-operator (n = 3) variation were determined by calculating the coefficient of variation from 5 repeated measurements for each peptide. In total 22 peptides (26%) were excluded from the dataset because of poor linearity and/or reproducibility of all its tested transitions (n = 3), no detectable signal for the endogenous peptide (n = 13), poor peak integration (partially outside scheduled detection window or split peaks) (n = 3) and one technical control. This resulted in selection of 64 distinct peptides for 32 different proteins to be measured in multiplex (Figs. 1, 2 and Table S3). For the ease of reading all peptide sequences in this study are abbreviated to the first three amino acids within brackets, as listed in Table S3.

3.3. Comparison to the current clinical standard

The MRM peptide levels of CRP (peptide ESD) were compared to clinical CRP protein values of the same patients, determined at the time of blood collection, measured with the highly standardized Roche/Hitachi cobas c system. Six patients were excluded from this analysis as no clinical CRP values were determined at the time of blood collection. We observed a strong correlation between the clinical CRP values and the levels of our LC-MS/MS analysis (Pearson’s r of 0.798) (Fig. 3). This indicates that, at least for CRP, the results from the MRM assay are comparable to clinical state-of-the-art measurements.

3.4. Complement levels in healthy individuals: age associated effect

To establish basal complement levels in healthy subjects from different age groups, we used the multiplex MRM assay to study all 64 peptides in plasma samples from healthy donors from 0 to 55 years old. Although the assay often includes multiple peptides originating from different parts of the same protein, we chose to analyze all MRM results at the peptide level instead of averaging all peptide results for one protein. Not all peptides originating from the same protein will give identical results. This is intrinsic to bottom-up proteomics due to differences in peptide stability, ionization efficiency and existence of multiple proteoforms [41–43]. Especially complement proteins have multiple proteoforms due to the proteolytic cleavages in the activation mechanism of the complement system.

When we compared the peptide levels between healthy adults (age 23–55) and healthy children (0–5) we found a high correlation, reflected by a Pearson’s r of 0.992 (Fig. 4a). Only when we compared the adult group to the healthy infants (<1 year old), we observe a decrease for the majority of the peptide levels for infants (Fig. 4b). To study the complement levels in more detail during early development the child control group was divided into four separate age classes: 0–6 months, 7–12 months, 13–24 months and 2–18 years old, which were then each compared to adult levels using ANOVA. Most of the peptides show an increasing trend during aging (Fig. 4c–e) and a limited number of these peptides had significantly lower levels in individuals of ≤6 months: C1QA (SLG), C1QB (FDH), C1QC (FQS) C1R (GYG), C5 (ILS, ITH, ELS), C8 (MES, IPG), C9 (VVE, LSP, TSN), C4BP (LSL, ALL), ficolin-3 (LLG), CFAB (DAQ, STG, YGL), and clustatin (ASS, IDS). The peptides of C1QC, C1R, Ficolin-3, C4BPA, C4BPP, FB reach the adult levels within one year (Fig. 4c), C5, C8A, C9 reach the adult levels after ≥1 year (Fig. 4d) and C1QA, C1QB, C8B, clustatin in 2 years (Fig. 4e). Remarkably, levels of two peptides situated in the beta chain of C5 appeared to increase again in adulthood (>18 years old). Furthermore, no gender associated effects were found for any of the peptides (Fig. 4f).

3.5. Complement levels in health and during infectious disease

The complement system acts as a cascade of chain-reactions and is quickly activated upon contact with antibodies (classical pathway), aberrant carbohydrate structures (lectin pathway) or foreign substances (alternative pathways). We investigated whether activation as a consequence of infection has an influence on the circulating levels of complement proteins. The multiplex MRM assay was used to compare the complement profiles between the group healthy (Fig. 5a) and infected individuals (Fig. 5b) by means of univariate correlation matrix profiles based on Pearson’s correlation and hierarchical clustering. A change in profiles was observed between the two groups, showing a stronger
correlation between the peptides in the infected group as compared to the control group, which is partly due to the slight increase in complement protein levels after infection.

On the contrary, some proteins were produced at lower levels in all patients as compared to controls, including C1QB (FDH, CNL), C1QC (FQS), C1R (GYG), C5 beta chain (ISL, ITH), C6 (ALN), C7 (LSG), clusterin (ASS), which are primarily the same proteins as those produced at lower levels during infancy (Fig. S4).

To further explore the differences between the controls and the patients with a viral or bacterial infection we performed principle component analysis (PCA) (Fig. 6a). The PCA score plot shows a separation between the control and patient sample clusters on the first PCA axis, accounting for 22% of the variation in the data. This discrimination was not influenced by gender (Fig. 6a). Both infection groups show a large overlap for all the principle components. The similarity between bacterial to viral infection for all peptides is emphasized by a correlation plot (Fig. 6b). Here, out of the 64 peptides, CRP (ESD), C4BPA (YTC) and clusterin (ASS, IDS) show an increased or a decreased ratio for a bacterial infection, respectively. By means of a t-test we determined which single peptides were significantly different between patients with a bacterial or a viral infection. CRP (ESD) levels were higher in the bacterial group as compared to the viral group, whereas clusterin (IDS) was significantly lower (Fig. 6c).

In order to assess if a combination of peptides can be used to discriminate the groups we used random forest analysis. The top five highest classifiers were CRP (ESD), clusterin (IDS, ASS), collectin11 (VFI) and C1QC (FQS) (Fig. 6d). To test if the random forest model based on all features could enhance the predictive power of CRP for bacterial infection we compared the area under the curve (AUC) of the receiver operating characteristic (ROC) curve for the clinical CRP levels (AUC = 0.9046) to the slightly higher random forest model (AUC = 0.9216) (Fig. 6e). This showed that our MRM assay is at least equally effective in predicting bacterial versus viral outcome as compared to the current clinical standard.

3.6. Following the kinetics of circulating complement proteins during bacterial infections

Apart from increased CRP (ESD) and reduced clusterin (ASS, IDS) levels, no other of the 64 complement peptide levels were significantly altered at the time the patient samples were collected for the clinical study. However, this is only a snapshot of the complement system at the start of infection, as the samples were taken shortly after admission to the hospital. In order to study the complement peptides during infection, we measured the levels of the complement peptides at multiple time points: within 24 h after hospital admission (T = 1), 48 h after hospital admission (T = 2), and at recovery (T = 3). We focused on infections with Streptococcus pyogenes, Neisseria meningitidis serogroup B, Streptococcus pneumoniae and Staphylococcus aureus (Full overview in Fig. S5).

In these longitudinal samples we observed that the peptide level of CRP (ESD) was decreased in time to basal levels for most patients (Fig. 7a), whereas clusterin peptide (ASS, IDS) levels increased (Fig. 7b), which seems to be the strongest and above basal levels for S. pyogenes and S. pneumoniae. Also MASP1 (SLP) (Fig. 7d) and factor H (SSN) (Fig. 7e) increased 2-fold after infection with S. pyogenes as compared to the other infections. These patients stayed relatively longer (average 31 days) in the hospital than the other patients (average 9 days), indicating a higher severity of infection. Although we expect a decrease to normal levels after complete recovery, we do not have any follow up samples to confirm this. Apart from these trends for S. pyogenes, we were not able to find other changes between the different types of infection or allocate distinct complement proteins that alter significantly in time; the majority of complement proteins did not show large fluctuations over time, as shown for ficolin3 (LLG) in Fig. 7f. Furthermore, we did not observe a difference in patterns between infection with Gram positive and Gram negative bacteria. An overview of all peptides is provided in Fig. S5.

4. Discussion

Multiple techniques and assays have been developed to measure concentrations of single complement proteins. However, complement proteins are part of a whole system acting in concert, which demands for a sensitive measurement to determine global changes in levels in a multiplex fashion. We used a targeted proteomics approach in which the mass spectrometer is programmed to detect specific peptides derived from the proteins of interest.

The MRM assay was technically validated based on linearity, intra-assay variation (reproducibility), inter-assay variation (robustness) and inter-operator variation. We found that 64 out of 86 targeted peptides were suitable (CV < 20% for the above mentioned parameters) to obtain a robust profile of 32 different complement proteins, indicating the importance of a technical validation as part of the assay development phase. Clinically determined CRP values of the patient cohort were used as a benchmark for the biological validation. We found that the CRP peptide levels measured by the MRM assay strongly correlated with the CRP levels measured by the highly standardized clinical assay. These technical and biological validation results provided a good foundation to continue with the data analysis of other complement levels in both healthy individuals and patients with infectious disease.

To our knowledge this is the first time that 32 complement proteins have been studied simultaneously in healthy individuals ranging from 0 to 55 years of age. We found some conflicting results in the literature concerning basal complement levels in young infants, the age that these levels reach adult levels and their dependency on gender [16,25]. In our study, no gender differences were observed for either the (pediatric or adult) control group or the patient group for any of the MRM complement peptides. Although gender–dependent differences in immune responses are known [44], it seems that this is not reflected by the expression levels of complement system components.
**Fig. 4.** Age-dependent complement levels, with (a) correlation plot for all 64 peptides, each indicated by a black circle, comparing a group of 20 adults to a group of 23 pediatric controls showing a Pearson r correlation of 0.592). A correlation coefficient of 1 is depicted by the dashed diagonal line. (b) Correlation plot for all 64 peptides comparing the adult controls to the infant controls (≤1 year). (c-e) The pediatric control group was divided into four separate age classes: 0–0.5 years, 0.5–1 years, 1–2 years, 2–18 years, 18–50 years old, where each marker represents one individual, including the mean and standard deviations per group. All groups were compared to the adult (18–50 years) class using ANOVA with Bonferroni’s Multiple Comparison test and significant trends were depicted in gray boxes (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). Different patterns of development to adult levels could be distinguished, showing representative figures for proteins reaching adult levels (c) within 1 year for peptide FB (YGL), (d) at 2 years (C9 (TSN)), or (e) after 2 years (C1QA (SLG)). (f) Gender differences were not observed for any of the peptides, as depicted by one representative plot with the gender groups for both the control and patient group for peptide FB (YGL). Graphs of all other peptides, comparing age and gender, can be found in the supplementary material.

**Fig. 5.** Comparing the complement peptides in health and disease. (a) Correlation matrix of all 64 peptides for all healthy controls. (b) Correlation matrix of all 64 peptides for all patients.
When we compared the age differences in our healthy individuals, we observed an equal distribution of complement levels among the pediatric and adult group. However, when looking at infant levels specifically, we did observe significantly lower levels for approximately one-third of the peptides; partially confirming earlier studies reporting lower levels in infants for most complement proteins [16].

To explain the biological background of the differences in levels between age groups for this distinct subset of complement proteins, we investigated possible associations with specific pathways, the location of protein production and the chromosomal locus. No specific relation with the site of production or chromosomal locus was found. However, there was a small trend in pathway specificity: lower infant levels were found for peptides from proteins at the beginning of the classical pathway (C1QA, C1QB, C1R). The majority of these peptides also decreased to lower levels during infection; whereas peptides that were at adult level during infancy stay at those adult levels during infection. Furthermore, it appeared that the majority of regulating (inhibitory) proteins, such as C1-inhibitor, factor D, factor H, factor I, were already at adult levels in newborns. This indicates that strict control of complement activation is important right after birth.

Moreover, from the data on the kinetics of complement proteins measured at hospital admission during infection and after recovery we deduce that this high rate of homeostasis of regulating proteins is also maintained during invasive bacterial infections.

Expression of the complement proteins appears surprisingly stable in patients challenged with bacterial or viral infections. This indicates
that there is no measurable consumption and suggests continuous replenishment of complement proteins. Furthermore, as expression of complement proteins is determined by constitutive rather than responsive expression it is conceivable that complement regulation takes place through both activation and post-translational modification. An exception to this observation is an increase and decrease of CRP and clusterin levels, respectively. CRP is currently used as clinical biomarker for bacterial infection. However, the exact function of clusterin in the context of infectious diseases is still unclear. Clusterin - or apolipoprotein J - is a stress-induced chaperone protein, which prevents the formation of the MAC-complex within the membrane by inhibiting C7, C8 and C9 [2]. Reduced levels of clusterin have previously been observed for sepsis patients [45] and even complete absence during malaria infections [46]. Also direct interaction of clusterin and pathogens [47,48], or their produced proteins [46,49], have been reported. In those cases clusterin prevented pathogen (protein) induced inflammatory responses [46], cell damage [45] or apoptosis [49]. Additional studies are required to further elucidate on its protective properties in infectious diseases.

Although we hypothesized that there might be pathway-specific altering complement levels in bacterial and viral infections, we only identified small differences in complement levels measured in plasma from children in this pilot study. The complement system did not seem to have pathogen-specific activation pathways reflected by altered expression levels of specific complement proteins.

A ROC curve based on the random forest model, trained on the highest discriminators, performs similarly to the current clinical assay. The MRM assay is thus a promising method to simultaneously profile the complement system and to serve as a diagnostic tool. However, this pilot study was conducted to demonstrate a new approach to study the complement system in a multiplex fashion. For diagnostic purposes the assay requires additional optimization such as the use of highly purified internal standards for absolute quantification and automation of the sample preparation procedure to enhance throughput and further reduce technical variability.

Especially for diagnostic purposes, absolute quantification is required in order to compare results analyzed at different laboratories and obtained with quantitative tests. Due to advancements in technology and development of new applications, Jannetto et al. envision an increasing trend in the implementation of mass spectrometry for clinical applications [50]. Although several mass spectrometers are listed as in vitro diagnostic medical devices, currently only one quantitative LC-MS assay kit has FDA clearance [51]. A standardized approach for development and verification was recently published by the Clinical and Laboratory Standards Institute (CLSI) to further enhance the implementation of this technology in clinical laboratories [51].

For instance, this MRM assay could then be a unique tool for monitoring other complement mediated diseases such as age-related macular degeneration (AMD), angioedema, antibody-mediated rejection, or autoimmune diseases like: rheumatoid arthritis (RA) atypical hemolytic uremic syndrome (aHUS), systemic lupus erythematosus (SLE) [52]. Furthermore, this MRM assay could help in quickly confirming a (suspected) complement deficiency, since this process now is very laborious consisting of several consecutive ELISAs to find the affected protein(s).

The requirement of little amounts of sample and the reducing conditions of the sample pretreatment prior to this mass spectrometric assay facilitate measurement of various sample types. With this multiplex assay we are currently able to measure complement peptides in serum, plasma, CSF, throat samples, nose swabs, urine and cell culture medium (data not shown). This creates opportunities to use this multiplex assay to investigate complement levels in other, less invasive, parts of the body and as readout of both in vitro experiments as well as (augmentation of) clinical diagnostics.

**Acknowledgments**

We thank the PERFORM consortium for their collaboration and fruitful discussions. We are thankful for the patient samples from the following infections: N. meningitidis (n = 3 individuals), S. aureus (n = 2), S. pneumoniae (n = 3) or S. pyogenes (n = 3), with T1 (hospital admission), T2 (48h post-admission) and T3 (recovery), compared to average child control values (± std.dev. indicated by gray area), depicted for the peptides (a) CRP (ESD), (b) clusterin (ASS), (c) clusterin (IDS), (d) MASP1 (SLP), (e) factor H (SSN), (f) ficolin3 (LLG). A heat map overview of all peptides is included in Fig. S5.
VENTURIUS, IRIS, and EUCLIDS study. We also would like to thank all healthy volunteers and the patients for donating their blood for these studies.

Funding sources
This research, part of the PERFORM project, has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 668303. The samples were collected previously funded by: the European Seventh Framework Programme for Research and Technological Development (FP7) under EUCLIDS Grant Agreement n°. 279185; Virgo consortium, funded by the Dutch Government project number FES0908 and by the Netherlands Genomics Initiative (NGI) project number 050-060-452; and the Immunopathology of Respiratory, Inflammatory and Infectious Disease Study (IRIS).

Declaration of interests
Dr. Alkema reports grants from European Commission, during the conduct of the study; Dr. van der Flier reports grants from CSL Behring, grants from Shire, outside the submitted work; Dr. Emonts reports grants from EU FP7, grants from European Union’s Horizon 2020 research and innovation program, during the conduct of the study; personal fees from Newcastle upon Tyne Hospitals NHS Foundation Trust, personal fees from Newcastle University, outside the submitted work; Dr. Irene Rivero-Calle reports other from Albynx, other from Janseen, other from GSK, other from Medimmune and other from Sanofi Pasteur; personal fees and other from Pfizer, personal fees and other from MSD; all outside the submitted work.

Author contributions
Conceptualization, E.W. and M.I.J.; Methodology, E.W., J.G. and M.I.J.; Investigation, E.W. and J.K.; Validation, E.W. and J.K.; Software, W.A. and M.F.; Writing Original Draft, E.W. and M.I.J.; Writing – Review & Editing, E.W. and M.I.J.; Supervision, J.G. and M.I.J.

Appendix A. Supplementary material
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.06.008.

References
[1] Nonaka M, Kimura A. Genomic view of the evolution of the complement system. Immunogenetics 2006;58(9):701–13.
[2] Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and pathogen clearance. Cell 2018;175(6):1371–91.e13.
[3] Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I–molecular mechanisms of activation and regulation. Front Immunol 2015;6:
[4] Merle NS, Noe R, Hallbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol 2015;6:
[5] Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states. J Intern Med 2010;267(7):686–97.
[6] Fish EN. The X-chromosome in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008;8(9):737.
[7] Bennett KM, Rooijakers SH, Gorham JR Jr. Let’s tie the knot: marriage of complement and adaptive immunity in pathogen evasion, for better or worse. Front Microbiol 2017;8:89.
[8] Botto M, Kirschning M, Macor P, Pickering MC, Würzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol 2009;46(14):2774–83.
[9] Emonts M, Hazelezet J, de Groot R, Hermans P. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003;3(9):565–77.
[10] Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007;7(5):379.
[11] Strunk T, Currie A, Richmonds P, Simmer K, Burgner D. Innate immunity in human newborns: prematurity means more than immaturity. J Matern Fetal Neonatal Med 2011;24(1):25–31.
[12] McGregor EP, Heare K, Spiller OB. Off to a slow start: under-development of the complement system in term and preterm infants is more substantial following premature birth. Immunology 2012;137(2):176–86.
[13] Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res 1979;13(9):1043.
[14] Johnston RB, Altenburger KM, Atkinson AW, Curry RH. Complement in the newborn infant. Pediatrics 1979;64(5):781–6.
[15] Shapero R, Beatty D, Woods D, Malan A. Serum complement and immunoglobulin values in small-for-gestational-age infants. J Pediatr 1981;99(1):139–41.
[16] Zilow G, Zilow EP, Burger R, Linderkamp O. Complement activation in newborn infants with early onset infection. Pediatr Res 1993;34(2):199.
[17] Wessela D, Volokhina EB, Van Der Molen RG, et al. Serological and genetic complement polymorphism in infection-induced and complement-mediated hemorrhagic syndrome. Pediatr Nephrol 2017;32(2):267–309.
[18] van Beek AE, Kampa A, Kruijtsf S, et al. Reference intervals of factor H and factor H-related proteins in healthy children. Front Immunol 2018;9.
[19] Ritchie RF, Palomaki GE, Navolotskaia O. Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world’s literature. J Clin Lab Anal 2004;18(1):9–13.
[20] Rother K, Till GO. The complement system. Springer Science & Business Media; 2012.
[21] Davis CA, Mogg, Poppelaars F, Van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front Immunol 2018;9.
[22] Harboe M, Thorsgeren EB, Mollnes TE. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2013;65(12):975–87.
[23] Rezei M, Végvári Á, Otterveld J, Olsson T, Laerul T, Marko-Varga G. MRM assay for quantification of complement components in human blood plasma—a feasibility study on multiple sclerosis. J Proteomics 2011;75(2):211–20.
[24] Rezei M, Végvári Á, Silajá E, et al. Inflammatory markers in Huntington’s disease plasma—a robust nanoLC-MS/MS assay development. EuPA Open Proteome 2014; 3:68–75.
[25] Yang L, Stewart T, Shi M, et al. An alpha-synuclein MRM assay with diagnostic potential for Parkinson’s disease and monitoring disease progression. PROTEOMICS-Clin Appl 2011;11(7-8):1700045.
[26] Zhang P, Zhu M, Geng-Sypropolous M, et al. A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CH) variants and CH-related proteins 1–5 in human plasma. Proteomics 2017;17(6).
[27] Cross TG, Hornshaw MP. Can LC and LC-MS ever replace immunoassay? J Appl Bionanos 2016;2(4):108.
[28] Bredsdor NF, Schlabach JJ, Griessen GJ, et al. Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-Threatening Infectious Disease Study (EUCLIDS). Crit Care 2018;22(1):134.
[29] Martinez-Torres F, Salas A, Rivero-Calle I, et al. Life-threatening infections in children in Europe (the EUCLIDS project): a prospective cohort study. Lancet Child Adoles Health 2018;2(6):404–14.
[30] Herberg JA, Kaflour M, Wright VJ, et al. Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children. Jama 2016;316(9):835–45.
[31] Ahout IM, Brand KH, Zomer A, et al. Prospective observational study in two Dutch hospitals to assess the performance of inflammatory plasma markers to determine disease severity of viral respiratory tract infections in children. BMJ Open 2017;7(6):e014596.
[32] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[33] Consortium T. UniProt: the universal protein knowledgebase. Nucleic Acids Res 2017;45(D1):D158-D69.
[34] Sherry ST, Ward M-H, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Genome Biol 2001;2(3):68.
[35] Consortium U. UniProt: the universal protein knowledgebase. Nucleic Acids Res 2017;45(D1):D158-D69.
[36] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[37] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[38] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[39] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[40] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[41] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[42] Desiere F, Deutsch EW, King NL, et al. The peptideatlas project. Nucleic Acids Res 2006;34(suppl_1):D655-D8.
[45] Jiří Ž, Michal F. Changes in the serum levels of clusterin in children with sepsis. Pediatr Pol 2013;88(1):6–13.
[46] Kassa FA, Shio MT, Bellemare M-J, Faye B, Ndao M, Olivier M. New inflammation-related biomarkers during malaria infection. PLoS One 2011;6(10):e26495.
[47] Partridge SR, Baker MS, Walker MJ, Wilson MR. Clusterin, a putative complement regulator, binds to the cell surface of Staphylococcus aureus clinical isolates. Infect Immun 1996;64(10):4324–9.
[48] Li D-Q, Ljungh Å. Binding of human clusterin by Staphylococcus epidermidis. FEMS Immunol Med Microbiol 2001;31(3):197–202.
[49] Tripathi S, Batra J, Cao W, et al. Influenza A virus nucleoprotein induces apoptosis in human airway epithelial cells: implications of a novel interaction between nucleoprotein and host protein Clusterin. Cell Death Dis 2013;4(3):e562.
[50] Jannetto PJ, Fitzgerald RL. Effective use of mass spectrometry in the clinical laboratory. Clin Chem 2016;62(1):92–8.
[51] Lynch KL. CLSI C62-A: a new standard for clinical mass spectrometry. Clin Chem 2016;62(1):24–9.
[52] Ekdahl KN, Persson B, Mohlin C, Sandholm K, Skattum L, Nilsson B. Interpretation of serological complement biomarkers of in disease. Front Immunol 2018:9:2237.